Related Experiment Video
Updated: May 21, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Targeting Huntington's disease through histone deacetylases
1Translational Cancer Research Group, Department of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital, James's Street, Dublin 8, Ireland.
Insights
Huntington's disease (HD) involves abnormal protein modifications, impacting neurodegeneration. Targeting histone deacetylases offers a potential therapeutic strategy for this condition.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Huntington's disease (HD) is a severe neurodegenerative disorder with limited treatment options.
- Aberrant post-translational modifications (PTMs) of proteins are increasingly recognized in HD pathogenesis.
- PTMs like acetylation, phosphorylation, methylation, sumoylation, and ubiquitination are implicated.
Purpose of the Study:
- To review the evidence linking aberrant PTMs to Huntington's disease.
- To explore the role of cellular machinery regulating PTMs in HD.
- To discuss potential therapeutic strategies targeting PTM-regulating proteins.
Main Methods:
- Literature review of current evidence on PTMs in HD.
- Analysis of the role of protein families regulating PTMs.
- Examination of therapeutic potential of targeting histone deacetylases.
Main Results:
- Aberrant PTMs are significantly associated with HD pathogenesis.
- Dysregulation of PTM-modulating cellular machinery contributes to HD.
- Histone deacetylases represent a promising therapeutic target.
Conclusions:
- Targeting aberrant PTMs and their regulatory proteins is crucial for HD treatment.
- Pharmacological inhibition of histone deacetylases shows therapeutic promise for Huntington's disease.
- Further research into PTMs could unveil novel treatment avenues for HD.
Abstract:
Huntington's disease (HD) is a debilitating neurodegenerative condition with significant burdens on both patient and healthcare costs. Despite extensive research, treatment options for patients with this condition remain limited. Aberrant post-translational modification (PTM) of proteins is emerging as an important element in the pathogenesis of HD. These PTMs include acetylation, phosphorylation, methylation, sumoylation and ubiquitination. Several families of proteins are involved with the regulation of these PTMs. In this review, I discuss the current evidence linking aberrant PTMs and/or aberrant regulation of the cellular machinery regulating these PTMs to HD pathogenesis. Finally, I discuss the evidence suggesting that pharmacologically targeting one of these protein families the histone deacetylases may be of potential therapeutic benefit in the treatment of HD.
Related Concept Videos
Huntington Disease l: Introduction
Pharmacogenomics: Identification of New Drug Targets
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...

